EA200800075A1 - Схема дозирования для празугреля - Google Patents

Схема дозирования для празугреля

Info

Publication number
EA200800075A1
EA200800075A1 EA200800075A EA200800075A EA200800075A1 EA 200800075 A1 EA200800075 A1 EA 200800075A1 EA 200800075 A EA200800075 A EA 200800075A EA 200800075 A EA200800075 A EA 200800075A EA 200800075 A1 EA200800075 A1 EA 200800075A1
Authority
EA
Eurasian Patent Office
Prior art keywords
wise
dosing circuit
prazogrel
administering
pharmaceutically acceptable
Prior art date
Application number
EA200800075A
Other languages
English (en)
Russian (ru)
Inventor
Джон Томас Бранд
Наги Альфонс Фарид
Джозеф Энтони Якубовски
Кристофер Дэвид Пэйн
Говинда Джаянат Уираккоди
Кеннет Джон Уинтерс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200800075A1 publication Critical patent/EA200800075A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA200800075A 2005-06-17 2006-06-13 Схема дозирования для празугреля EA200800075A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17
PCT/US2006/023006 WO2006138317A2 (en) 2005-06-17 2006-06-13 Dosage regimen for prasugrel

Publications (1)

Publication Number Publication Date
EA200800075A1 true EA200800075A1 (ru) 2008-04-28

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800075A EA200800075A1 (ru) 2005-06-17 2006-06-13 Схема дозирования для празугреля

Country Status (18)

Country Link
US (1) US20090156632A1 (https=)
EP (1) EP1893205A4 (https=)
JP (1) JP2008543853A (https=)
KR (1) KR20080016647A (https=)
CN (1) CN101198329A (https=)
AU (1) AU2006259538A1 (https=)
BR (1) BRPI0612624A2 (https=)
CA (1) CA2612315A1 (https=)
EA (1) EA200800075A1 (https=)
EC (1) ECSP078014A (https=)
GT (1) GT200600263A (https=)
IL (1) IL187486A0 (https=)
MA (1) MA29722B1 (https=)
MX (1) MX2007015430A (https=)
NO (1) NO20080244L (https=)
TN (1) TNSN07474A1 (https=)
WO (1) WO2006138317A2 (https=)
ZA (1) ZA200710769B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物
US9034860B2 (en) 2006-12-07 2015-05-19 Daiichi Sankyo Company, Limited Pharmaceutical composition containing low-substituted hydroxypropyl cellulose
JP5681485B2 (ja) 2007-04-27 2015-03-11 サイデックス・ファーマシューティカルズ・インコーポレイテッド クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
CA2761455C (en) 2009-05-13 2018-06-12 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
AU2001267916B2 (en) * 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
AU2002217464B2 (en) * 2000-12-25 2004-12-16 Daiichi Sankyo Company, Limited Medicinal compositions containing aspirin
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
US20060217351A1 (en) * 2003-05-05 2006-09-28 Brandt John T Method for treating cardiovascular diseases

Also Published As

Publication number Publication date
GT200600263A (es) 2007-02-23
MA29722B1 (fr) 2008-09-01
US20090156632A1 (en) 2009-06-18
JP2008543853A (ja) 2008-12-04
CN101198329A (zh) 2008-06-11
WO2006138317A3 (en) 2007-05-03
ZA200710769B (en) 2009-09-30
BRPI0612624A2 (pt) 2016-11-29
EP1893205A2 (en) 2008-03-05
ECSP078014A (es) 2008-01-23
CA2612315A1 (en) 2006-12-28
IL187486A0 (en) 2008-06-05
KR20080016647A (ko) 2008-02-21
EP1893205A4 (en) 2010-06-30
NO20080244L (no) 2008-01-14
AU2006259538A1 (en) 2006-12-28
MX2007015430A (es) 2008-02-21
WO2006138317A2 (en) 2006-12-28
TNSN07474A1 (en) 2009-03-17

Similar Documents

Publication Publication Date Title
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
TNSN07474A1 (en) Dosage regimen for prasugrel
MXPA05012810A (es) Formas de dosis oral de memantina.
ATE464052T1 (de) Neue pharmazeutische verwendungen von staurosporin-derivaten
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
TW200626133A (en) Oral medication for twice-daily administration
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера
RU2007129408A (ru) Способ выращивания поросят в период откорма
RU2003124971A (ru) Способ лечения больных с невротическими и соматоформными расстройствами
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
RU2003123827A (ru) Способ комбинированного лечения стронгилятозов животных
CR9572A (es) Regimen de dosificacion para prasugrel
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit